References

Titin antibodies in “seronegative” myasthenia gravis–a new role for an old antigen

10.1016/j.jneuroim.2016.01.018 · 2016 · External reference

Clinical characteristics and treatment outcomes in patients with double-seronegative myasthenia gravis

10.1016/b978-0-12-374279-7.15006-4 · 2024 · External reference

Seronegative myasthenia gravis—a vanishing disorder

10.1001/jamaneurol.2016.2277 · 2016 · External reference

Differential expression profiles of lncRNAs and a preliminary study on the mechanism of lncRNA FAM225A in triple seronegative myasthenia gravis

10.3389/fimmu.2025.1664131 · 2025 · External reference

艾加莫德联合利妥昔单抗治疗以呼吸困难起病的MuSK抗体阳性重症肌无力1例报道

10.3969/j.issn.1006-2963.2025.06.004 · 2025 · External reference

Rituximab in new-onset generalized myasthenia gravis: long-term follow-up of the RINOMAX clinical trial

10.1111/ene.70418 · 2025 · External reference

High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria

10.1007/s00415-019-09191-6 · 2019 · External reference

Effectiveness and safety of rituximab for refractory myasthenia gravis: a systematic review and single-arm meta-analysis

10.3389/fneur.2021.736190 · 2021 · External reference

Efficacy and safety of low-dose rituximab in the treatment of myasthenia gravis: a systemic review and meta-analysis

10.3389/fneur.2024.1439899 · 2024 · External reference

Open-label study of efgartigimod in seronegative myasthenia gravis

10.1177/17562864251388019 · 2025 · External reference

Efgartigimod improves non-AChR generalized myasthenia gravis: a real world experience

10.1007/s10072-025-08096-9 · 2025 · External reference

Efgartigimod improved health‐related quality of life in generalized myasthenia gravis: results from a randomized, double‐blind, placebo‐controlled, phase 3 study (ADAPT)

10.1007/s00415-022-11517-w · 2023 · External reference

中国重症肌无力诊断和治疗指南(2025版)

10.3760/cma.j.cn113694-20250120-00041 · 2025 · External reference

Overcoming therapeutic challenges: successful management of a supposedly triple seronegative, refractory generalized myasthenia gravis patient with efgartigimod

10.1111/ene.16306 · 2024 · External reference

Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update)

10.1136/pn-2025-004655 · 2025 · External reference